Literature DB >> 14597675

Differential regulation of in vivo angiogenesis by angiotensin II receptors.

Thomas Walther1, Andreas Menrad, Hans-Dieter Orzechowski, Gerhard Siemeister, Martin Paul, Michael Schirner.   

Abstract

Angiotensin II (ANG II), a key regulator of blood pressure and body fluid homeostasis, exerts mitogenic effects on endothelial cells. We therefore hypothesized that ANG II could be a mediator between homeostatic changes within the vascular perfusion bed and growth factor-driven angiogenesis. In the present study, we applied the alginate implant angiogenesis model in mice with normal ANG II levels, elevated ANG II levels by transgenic overexpression of angiotensinogen (AOGEN), or in AT2 receptor-deficient mice. We demonstrate that a decrease in the amount of circulating ANG II by the angiotensin-converting enzyme (ACE) inhibitor enalapril or the AT1 receptor antagonist losartan induced a stimulation of in vivo angiogenesis implying an inhibitory function of ANG II through the AT1 receptor. However, the strong increase of angiogenesis in AOGEN-transgenic mice compared with mice with normal ANG II levels suggests additional stimulatory activity. We showed that the ANG II-induced stimulation of angiogenesis is linked to the AT2 receptor as an impaired induction of angiogenesis was obtained in AT2 receptor knockout mice. These findings provide the first evidence that the AT2 receptor mediates a stimulation of in vivo angiogenesis and indicate that ANG II is a humoral regulator of peripheral angiogenesis involving two receptor subtypes with opposing actions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14597675     DOI: 10.1096/fj.03-0129com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  32 in total

Review 1.  Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials.

Authors:  Ilke Sipahi; Sara M Debanne; Douglas Y Rowland; Daniel I Simon; James C Fang
Journal:  Lancet Oncol       Date:  2010-06-11       Impact factor: 41.316

2.  Is there a link between angiotensin receptor blockers and cancer?

Authors:  Frank Enseleit; Frank Ruschitzka
Journal:  Curr Hypertens Rep       Date:  2011-02       Impact factor: 5.369

Review 3.  Redox-dependent mechanisms in coronary collateral growth: the "redox window" hypothesis.

Authors:  June Yun; Petra Rocic; Yuh Fen Pung; Souad Belmadani; Ana Catarina Ribeiro Carrao; Vahagn Ohanyan; William M Chilian
Journal:  Antioxid Redox Signal       Date:  2009-08       Impact factor: 8.401

4.  Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: a population-based case-control study.

Authors:  Jesper Hallas; Rene Christensen; Morten Andersen; Søren Friis; Lars Bjerrum
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

Review 5.  Angiotensin II regulation of ovine fetoplacental artery endothelial functions: interactions with nitric oxide.

Authors:  Jing Zheng; Ian M Bird; Dong-Bao Chen; Ronald R Magness
Journal:  J Physiol       Date:  2005-03-24       Impact factor: 5.182

6.  Renin and angiotensin-converting enzyme (ACE) as active components of the local synovial renin-angiotensin system in rheumatoid arthritis.

Authors:  Veli Cobankara; Mehmet Akif Oztürk; Sedat Kiraz; Ihsan Ertenli; Ibrahim C Haznedaroglu; Salih Pay; Meral Calgüneri
Journal:  Rheumatol Int       Date:  2005-03-11       Impact factor: 2.631

7.  Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies.

Authors:  Chan Yoon; Hyun-Sik Yang; Inpyo Jeon; Yoosoo Chang; Sang Min Park
Journal:  CMAJ       Date:  2011-08-29       Impact factor: 8.262

8.  Angiotensin type I receptor blockade in conjunction with enhanced Akt activation restores coronary collateral growth in the metabolic syndrome.

Authors:  Rashmi Jadhav; Tracy Dodd; Erika Smith; Erin Bailey; Angelo L Delucia; James C Russell; Rowan Madison; Barry Potter; Kenneth Walsh; Hanjoong Jo; Petra Rocic
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-02-18       Impact factor: 4.733

9.  Melanoma and Non-Melanoma Skin Cancer Associated with Angiotensin-Converting-Enzyme Inhibitors, Angiotensin-Receptor Blockers and Thiazides: A Matched Cohort Study.

Authors:  Beatrice Nardone; Sara Majewski; Ashley S Kim; Tina Kiguradze; Estela M Martinez-Escala; Rivka Friedland; Ahmad Amin; Anne E Laumann; Beatrice J Edwards; Alfred W Rademaker; Mary C Martini; Dennis P West
Journal:  Drug Saf       Date:  2017-03       Impact factor: 5.606

10.  Angiotensin II increases angiogenesis by NF-κB-mediated transcriptional activation of angiogenic factor AGGF1.

Authors:  Wenxia Si; Wen Xie; Wenbing Deng; Yi Xiao; Sadashiva S Karnik; Chengqi Xu; Qiuyun Chen; Qing Kenneth Wang
Journal:  FASEB J       Date:  2018-04-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.